Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
administered a late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 60-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received first dose 5 months ago in 2025). In MAR-2026, the patient received the 2nd dose of Twinrix. In MAR-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: administered a late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-MAR-2026 The pharmacist called to explain that a patient had received a dose of Twinrix and that a late second dose had been administered five months later during the previous week. The health care professional asked when the third dose was due after the late second dose. The batch number was not provided and a request for this information has been made.